Born out of a $5.2M NIH research grant at Brigham Young University, Diagnostic Ventures is a proud Utah-native startup on a mission to transform sepsis care. We are engineering a diagnostic solution that replaces traditional blood cultures, eliminating critical wait times and empowering providers to save lives.
Disclaimer: This product is currently under development and is not yet FDA-approved or available for commercial sale.
Our technology isolates pathogens directly from a whole blood, bypassing traditional culture processes. It then uses microfluidics, raman spectroscopy and machine learning to quickly identify bacteria.
50 Million Sepsis Infections 2
11 Million Sepsis Deaths 2
1 in 5 Deaths Caused by Sepsis 3
.png)
.png)
.png)
.png)
.png)
